In summary, we provided a chimeric ubiquitin ligase, SH2-U-box, which can target both the wide type and BCR-ABL T315I that exist in imatinib-sensitive or -resistant CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.